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Abstract HIV testing uptake has increased dramatically
in recent years in resource limited settings. Nevertheless,
over 50 % of the people living with HIV are still unaware
of their status. HIV self-testing (HIVST) is a potential new
approach to facilitate further uptake of testing which
requires consideration, taking into account economic fac-
tors. Mathematical models and associated economic ana-
lysis can provide useful assistance in decision-making
processes, offering insight, in this case, into the potential
long-term impact at a population level and the price-point
at which free or subsidized HIVST would be cost-effective
in a given setting. However, models are based on
assumptions, and if the required data are sparse or limited,
this uncertainty will be reflected in the results from math-
ematical models. The aim of this paper is to describe the
issues encountered in modeling the cost-effectiveness of
introducing HIVST, to indicate the evidence needed to
support various modeling assumptions, and thus which data
on HIVST would be most beneficial to collect.
Keywords HIV self-testing  Modelling  HIV  Cost-
effectiveness  Data
Background
The scale up of antiretroviral therapy (ART) in resource
limited settings (RLS) has transformed HIV from a ter-
minal illness to a chronic condition. Nevertheless, many
people living with HIV in need of ART still do not access
it, or HIV care more broadly, because they are unaware of
their HIV status. This results in increased morbidity and
mortality [1, 2] and potentially higher risk behavior, as
undiagnosed individuals may not have the motivation to
reduce condomless sex that an HIV diagnosis can induce
[3–6]. Importantly, low uptake of HIV testing will also
limit effective implementation of new prevention strate-
gies including male circumcision [7–9], vaginal, rectal
and oral pre-exposure prophylaxis [10] and early ART
[11]. Despite a dramatic increase in HIV testing in recent
years in most sub-Saharan African countries, over 50 %
of people living with HIV are unaware of their HIV status
[12]. The reasons for not actively seeking an HIV test
through current provider-delivered strategies (referred
from now on as ‘‘HIV testing and counselling’’ (HTC),
regardless of whether it is a client-initiated such as stan-
dard voluntary counselling and testing, or provider-initi-
ated strategy, or of the location where it is performed) are
numerous, including fear of stigma and discrimination,
perceived lack of confidentiality, and the inconvenience
and opportunity costs of testing [13]. Many of these
barriers may be addressed through HIV self-testing
(HIVST). HIVST consists of an individual collecting their
own sample (typically saliva or a finger prick blood
sample), and performing the HIV test on their own [14].
Though the idea of HIVST has been debated for over two
decades, regulated HIVST kits are generally not available,
with the United States and Kenya being among the few
exceptions.
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Given the imperative of expanding HIV testing uptake
and frequency, it is important to consider new delivery
strategies such as HIVST. The aim of this paper is to
describe the issues encountered in modeling the potential
effectiveness and cost-effectiveness of HIVST, to highlight
what evidence exists to support assumptions, and to iden-
tify the areas where additional research is required in order
to reduce uncertainty around these parameters. Ultimately,
this will result in better-informed decision making around
HIVST policy and programming.
Rationale for Modeling HIV Self-Testing
Globally, donors and other stakeholders are considering
whether investments should be made in the marketing and
delivery of HIVST, in order to increase uptake of HIV
testing. To maximize public health benefits, generally only
cost-effective interventions should be introduced.
In RLS, preliminary research has been conducted in
Kenya, Malawi and South Africa demonstrating high
uptake, relatively good accuracy, and the potential to link
self-testers to care [15–19]. However, we lack data on a
number of other important factors including the increase in
rate of first-time and repeat testing, the level of confirma-
tory testing, the long-term impact of introducing HIVST
and its cost. Mathematical models can help us make best
use of available data and provide insight into the potential
impact of HIVST at a population level, including over the
longer term, and can help determine whether the intro-
duction of free or subsidized HIVST kits would be cost-
effective. A summary of the issues involved in modelling
HIVST is provided in Table 1.
Several mathematical models have evaluated the impact
and/or cost-effectiveness of expanding HTC in some high
income [20–25] as well as low and middle income countries
[26–29]. All found that HTC could be cost-effective in some
circumstances, although at different frequencies and at dif-
ferent cost per quality adjusted life-year gained or disability
adjusted life-year averted.Factors that have been found to
influence the cost-effectiveness of HTC include: HIV inci-
dence [28], HIV prevalence [26], prevalence of undiagnosed
HIV infection [23], whether key populations were targeted
[25], HTC cost [28], ART costs [28], and whether averting
tertiary infections was taken into account [28].HIVST could
lead to increased HIV testing, but to evaluate its effectiveness
and cost-effectiveness it is necessary to take into consider-
ation differences between HIVST and HTC.
Just one modeling study of HIVST has been conducted,
among men having sex with men (MSM) in Seattle, USA.
This study assessed the impact on HIV prevalence of
replacing clinic-based HTC with HIVST [30]. The authors
concluded that any replacement of clinic-based HTC with
HIVST would increase HIV prevalence due to the longer
‘‘window period’’ (i.e. the time between initial HIV
infection and when the test can reliably detect the infec-
tion) of the HIVST as compared to antigen–antibody
combination tests used in some clinics [30]. However,
currently in RLS antibody–only tests are also used by
providers.To our knowledge, the cost-effectiveness of
introducing HIVST in RLS, using a mathematical model,
has not yet been evaluated.
A Modeler’s ‘Wish List’ for HIV Self-Testing
Building a model requires a detailed hypothesis for how a
process—in this case the introduction of HIVST—could
work and which parameters need to be defined, and if
possible estimated from data. The parameters characterized
by high levels of uncertainty are usually varied in sensi-
tivity analysis to understand how they affect the results and
therefore what the impact might be of a wrong assumption.
Mathematical models designed to evaluate HIVST need
to be dynamic and to consider testing in HIV positive and
HIV negative people, levels of sexual risk behavior, and
model the risk of acquiring HIV as a function of sexual risk
behavior. Models also need to distinguish between HTC,
which if positive implies diagnosis, and HIVST, which
would require the additional step of confirmatory HTC
before a person is considered diagnosed. A simple illus-
tration of how HIVST could be included in a mathematical
model is provided (Fig. 1).
Proportion of People who do not Test Under Provider-
Delivered Testing Strategies(Issue 1 in Table 1)
Although acceptability of HTC is generally high, there is
substantial variability in uptake [31]. Furthermore, testing
uptake varies considerably based on socio-demographic
characteristics [12]. It is therefore necessary to define a
proportion of the population as ‘resistant to testing’,
meaning they would not utilize HTC.
Uptake of Self-Testing Among Those Resistant
to Testing (Issue 2 in Table 1)
It is necessary to quantify how many people might self-test
from among those who are resistant to testing by existing
available means. Several studies have evaluated hypothetical
acceptability of HIVST [16, 32–37], while fewer have eval-
uated actual uptake when made available, and in particular
among people who would not have accepted HTC [16, 17, 19,
38–40]. In a study conducted in Malawi, where HIVST was
made available through community counsellors, 76 % of over
16,000 residents had used HIVST at 12 months since its
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introduction, with 43 % being first time testers [39]. A study
conducted among healthcare workers in 7 hospitals in Kenya
found that the uptake was 89 %. Among healthcare workers
who self-tested, most (92 %) had tested before, and from these
data we cannot estimate how many of those who accepted the
HIVST were resistant to HTC [17]. Similarly a pilot study
conducted among healthcare workers in Cape Town, reported
a 93 % uptake of unsupervised HIVST [19], with 13 % being
first time testers.
Other studies have evaluated the uptake of HIVST,
without distinguishing whether these people were resistant
to HTC or not, nor on whether they were first-time or
repeat tests [38]. A recent meta-analysis, for example,
estimated uptake of HIVST to be 87 % [41].
Impact of Self-Testing Availability on the Rate of HIV
Testing Among Those not Resistant to Testing (Issue 3,
6 and 7 in Table 1)
We are also interested in the extent to which availability of
HIVST would, by providing a convenient and confidential
option, increase the probability of testing in people who are
not resistant to HTC but have never been tested before;
similarly, we are interested in the frequency of repeat
HIVST. To our knowledge the only relevant information
available comes from a study among MSM in Australia,
which found that 66 %reported that they would test more
often if HIVST were available [42].
Replacement of Provider-Delivered Testing with Self-
Testing (Issue 4 in Table 1)
A further important consideration is what proportion of
future tests via HTC would be conducted via HIVST if
available. Again, this might be different for first time versus
repeat testing and will depend on the cost of different
strategies. It may be cost-saving to introduce HIVST if its
provision is less expensive than HTC, despite its lower
sensitivity and the necessity for confirmatory HTC for those
self-testing positive. It is therefore important to quantify the
extent and characteristics of those who replace HTC with
HIVST, particularly regarding sexual behaviour. The only
research which provides some indication of this parameter
is reported preferences for HIVST versus HTC methods,
and these data are largely from high income countries
Fig. 1 Example of parameterization of self-testing in a mathematical
model (Synthesis model [57, 58]). Illustration of features of a model
incorporating HIVST—the section of the graph in grey only applies if
HIVST is introduced. Features such as the level of sexual behaviour and
whether the person is truly HIV infected would be included in such a
model but are left cut here for the purposes of simplification. People can
be tested for the first time using a provider delivered HTC at a different
rate (in the model this rate may depend on sexual behaviour, age, gender,
presence of symptoms and other factors). If HIV negative they
respectively move or remain in the group of those who tested before for
HIV, while if HIV positive are considered diagnosed with HIV. At this
stage they experience a certain rate of having the 1st ART eligibility
assessment, and once this is completed of being enrolled into pre-ART
care, if not eligible for ART, or to be initiated on ART if eligible. Whether
in pre-ART care or on ART, they can be lost from care and return back
into care. If a person with HIV is self-tested for HIV, they have a chance
equal to the sensitivity of the self-test (SE) that the result of the test is
positive. If the test result is positive the person is not considered diagnosed
with HIV, but there is a certain rate with which they will have a
confirmatory provider-delivered HTC. For simplicity of illustration in
this graph we have assumed that the test provider by a trained person is
100 % accurate and that the specificity of the self-test is 1. If a person has a
self-test and either is not infected with HIV or, if HIV?, with a probability
of (1-SE) the person would remain in the group of those who tested
before for HIV. People with HIV diagnosed via self testing positive then
follow the same path as those who tested for HIV using provider delivered
HTC, although the rate at which they have the 1st ART eligibility
assessment could differ. At these different stages the risk of morbidity and
mortality and of infecting other people [not illustrated in the Figure)
varies In the Synthesis model the risk of morbidity and mortality depends
on age and gender and for people HIV-positive as well on CM-count, viral
load, ART and PCP prophylaxis; while the risk of transmission mainly on
the HIV-RNA level of the partner the person has condom-less sex with
(Further details are available in [53, 54]).
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[16, 33, 43–46]. We may not be able to accurately estimate
this parameter until HIVST is more widely available.
Characteristics of People who opt for Self-Testing
(Issue 5 and 8 in Table 1)
One of the advantages of HIVST is the potential for increased
confidentiality, which could appeal to marginalized groups
who are often more affected by stigma and discrimination,
such as sex workers and MSM. To our knowledge there are
no available data on the uptake of HIVST in these key groups.
Mathematical models are a simplification of reality, so they
would not include all variables which characterize these
groups: ours for example could incorporate dependence on
age, gender and sexual behaviour while other models may
include specific subgroups, characterized by different routes
of HIV transmission.
This parameter is particularly important because if
HIVST availability encourages testing in those resistant to
testing, and who are at increased risk of HIV, this could
impact their risk behaviour and/or their infectiousness (if
they receive ART), and therefore potentially reduce the
number of new infections they contribute to.
Accuracy of Self-Testing (Issue 10 and 11 in Table 1)
Poor accuracy of HIVST has long been a concern [47]. The
Food and Drug Administration approved OraQuick in-
Home HIV test kit has over 99 % sensitivity and specificity
when conducted and interpreted by trained providers [48,
49], and when conducted by lay people but read by a
provider [34]. When conducted and interpreted by lay
people specificity remains over 99 % [16, 19, 49, 50],
while sensitivity varies from 66.7 % (95 % CI: 30.9-91.0),
reported in a small pilot study of unsupervised HIVST
conducted among health care workers in South Africa, up
to over 99 % [16, 19, 50, 51]. Minor procedural errors and
request for extra help have been reported in a small pro-
portion (10 %) of populations evaluated [16]. There are
several studies on-going evaluating the accuracy of kits for
HIVST by lay people.
Confirmatory Testing Following a Positive Self-Test
(Issue 9 in Table 1)
A crucial modelling parameter is how many of those who
test HIV positive by HIVST have a subsequent confirma-
tory HTC, which can allow them to be formally diagnosed
and to initiate linkage to care and treatment. This parameter
is difficult to measure given the private nature inherent to
HIVST. Some indirect indication comes from a cluster
randomized trial conducted in Malawi evaluating home-
based assessment and initiation of ART in the context of
HIVST [15]. They found that the offer of home-based
assessment and initiation of HIV care significantly
increased the willingness to report positive self-test results,
and led to a three-fold rate of ART initiation in the first
6 months as compared to receiving facility-based HIV care
alone [15, 18], suggesting that without such home-based
assessment a high proportion of people who self-test
positive may not present for confirmatory HTC. These
findings potential underestimate the proportion of people
who would link to care, due to the short observation period
and the fact that the measurement of linkage to care was
based on the individual informing the clinic of having had a
positive HIVST. More recent data from this study [39]
indicate that 89 % of used HIVST kits distributed were
returned. Analysis of results of these used kits suggests that
75 % of positive results were disclosed to a counsellor. If
this disclosure meant they had a confirmatory HTC this
would suggest around 75 % of positives were ‘diagnosed’.
‘‘Linkage and Retention in Care’’ Following a Reactive
Self-Test Result (Issue 15 and 16 in Table 1)
A further concern is the possibility for low levels of linkage
into care and treatment after HIVST, as well as, differential
retention in care after confirmatory HTC (i.e. the person is
truly diagnosed, from the health system perspective). This is
an issue providers already struggle with under the current
HIV testing strategies. If the population choosing to self-test
is fundamentally different from those who choose HTC (for
example, more marginalized), it is possible that linkage and
retention in care after diagnosis may be more challenging.
In the control arm of the Malawi cluster randomized
trial, despite a dramatic increase in the number of people
testing for HIV with the introduction of HIVST, the pro-
portion who linked to care was similar to that in the
background population where only HTC was available
[18]. One year after HIVST and home assessment was
made available, 78 % of those who disclosed their reactive
HIVST result to counsellors linked to care [39]. There are
no other data on this topic to the best of our knowledge,
though research is currently underway.
Psychological Impact of HIV Self-Testing (Issue 14
in Table 1)
The psychological impact of receiving a positive HIVST
result without the immediate support of a counselor also
needs consideration. This could have implications for cost-
effectiveness, since a lower quality of life among a pro-
portion of these individuals would be factored into mea-
sures of effectiveness (quality adjusted life-years or
disability adjusted life-years). The few data available
showed very little evidence of serious harm [39], and there
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are no comparisons to the psychological impact via other
testing methods [52]. Further research on this topic is
currently underway.
Change in Sexual Behavior Following Self-Testing
(Issue 12 in Table 1)
There is evidence that people who test HIV-positive
through voluntary counselling and testing have reduced
sexual risk behavior [6]. Among those who tested HIV-
negative, there was no evidence of behavior change [6].
With provider-initiated testing and counselling [53], most
studies, but not all, reported an increase in condom use in
both people who tested HIV-negative and positive. To our
knowledge the only data available on the potential change
in risk behavior following HIVST come from a study
among MSM, where they reported that the 10 people
identified as HIV positive through HIVST did not have
sexual intercourse after learning their result [38].
Cost of Self-Testing (Issue 13)
A few studies have highlighted that cost is potentially a
significant barrier to accessing HIVST, even in high income
countries [34, 54, 55], given that where currently available
they must be purchased, while HTC is generally free.
Cost is likely to be an even greater barrier to HIVST in
RLS. Research studies so far have distributed them for free
in order to evaluate the uptake of HIVST. The most widely
available oral fluid–based test, OraQuick ADVANCE Rapid
HIV 1/2, is among the most expensive of the leading rapid
tests, costing around US$4 in RLS [56]. The method of
distribution is likely to have a major impact on the cost of
HIVST, as well as most of the other parameters discussed
here. Distribution is therefore fundamental when considering
the impact of the HIVST parameters described here.
Conclusion
HIV self-testing has great potential to increase knowledge
of HIV status in RLS, where over half of HIV-infected
individuals are currently unaware of their status. However,
the question remains as to whether the introduction of
HIVST would be effective and cost-effective.
Mathematical modelling can help to answer this ques-
tion, though field data is required in order to accurately
estimate important model parameters. In this paper we
have outlined the most important of these parameters,
which include the level of replacement of HTC with
HIVST, the increase in the rate of first-time and repeat
testing, and the level of confirmatory testing and linkage to
post-test care, among others (Table 1). The definition of
these parameters reflects the way we have attempted to
model HIVST, but different models could conceive and
structure the way in which HIVST impacts the HIV epi-
demic in a different way. While some field data exist, there
are several HIVST parameters for which evidence is lim-
ited. To increase the accuracy of our model it is necessary
to collect more data from well-powered studies. If accurate
mathematical models can be developed to inform effec-
tiveness and cost-effectiveness, they will be an important
tool to guide policy and programming around HIVST, and
ultimately to increase knowledge of HIV status and reduce
transmission in countries which need it most.
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